PATENT CLAIM ANALYSIS

Application Number: 16247133
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "018100"]

Abstract:
The invention provides methods and materials for treating a seizure disorder such as epilepsy in a patient which employ a vector encoding a modified receptor, the so-called “DREADD” receptor being characterised by (i) a decreased responsiveness to its endogenous activating ligand (ii) a retained or enhanced responsiveness to an exogenous agonist. The modified receptor is expressed in neurons of a seizure focus in brain of the patient, and an exogenous agonist is administered which activates the modified receptor to reversibly alters the excitability of the neurons in the seizure focus leading to synaptic silencing or other inhibition.

Claim (Index 1):
A method of treating a seizure disorder, which is focal epilepsy, in a patient suffering from said disorder,\n wherein either (a) said patient has previously been administered a vector encoding a modified receptor, wherein the modified receptor is a human muscarinic acetylcholine receptor M4, which is a Gi protein-coupled receptor (GPCR), coupled via a Gi-protein to a G protein-coupled inwardly rectifying potassium channel (GIRK), and wherein the modified receptor is characterised by (i) a decreased responsiveness to its endogenous activating ligand and/or (ii) a retained or enhanced responsiveness to an exogenous agonist, or (b) administering to the patient said vector, wherein the modified receptor is encoded by a nucleic acid operably linked to a neuronal cell type-specific promoter such that said modified receptor is expressed in excitatory neurons of a seizure focus in brain of the patient; which method comprises subsequently administering to said patient said exogenous agonist wherein the exogenous agonist is a clozapine-related ligand, whereby the presence of said agonist in the brain of the patient activates said modified receptor, whereby activation of said modified receptor reversibly inhibits the excitability of, and neurotransmission by, the excitatory neurons in the seizure focus.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 99.0
- Lexical Diversity: 1.64615
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15125762', '14281584', '15561547', '12466208', '13773416']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7144816868274564
- 35 USC 102 Novelty (BERT): 0.6854287869308011
- Combined Prediction Score: 0.7115763968377908
- Mean Citation Score: 327.15514399999995
- Max Citation Score: 683.1
- Similarity Product: 663.4137650370599

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test